Lysine Proline Valine Tripeptide
A synergistic blend of highly orally bioavailable KPV peptide with Palmitoylethanolamide (PEA), Hyaluronic Acid (HA), and Sodium Bicarbonate (Stomach acid buffer/Peptide absorption enhancement) to deliver superior full body regeneration.
How long before I see results?
How long before I see results?
Our customers typically see results within 1 month of taking the product.
KPV TRIPEPTIDE COMPLEX
A synergistic blend of the a-MSH tripeptide fragment, KPV with PEA (Palmitoylethanolamide) to deliver superior full body regeneration.
Paired with Sodium Bicarbonate to improve peptide absorption in a Delayed Release, enteric coated vegetable capsule to best bypass stomach acid peptide degredation.
Each bottle contains 60 capsules; 30 serves.
*This product is intended for research purposes only. All product information available on the website is for educational purposes only. Bodily introduction of any kind into humans is done at the person’s own risk, and LVLUP Health assumes no responsibility for health outcomes, good or bad that may result from ingestion or use of these experimental biologicals. Use should be supervised by a qualified healthcare professional.
- Aids in healing of injuries and wounds
- Potent Anti-Inflammatory
- Heal and enhance overall gut health
- Reduce pro-inflammatory cytokines
- Enhances collagen production and formation
- Improves skin health
- Strengthens Immune System
- Anti Microbial
- Anti Inflammatory
- Blocks mast cells degranulation (Antihistamine)
- Binding affinity for cannabinoid receptors (similar effects in the body as cannabis CBD oil)
- Reduces the expression of cyclooxygenase-2 (COX-2)
- Inhibits the release of histamine and TNF-alpha
- Relieves Pain (Analgesic)
Hyaluronic Acid (HA)
- Polysaccharide that occurs in high amounts in the skin, joints, and eyes
- Provides lubrication and keeping tissues hydrated
-Assist in wound, gut and connective tissue healing
- Protect against a number of respiratory diseases
- Assist with weight loss
- Brain health
-Assist in wound, gut and connective tissue healing
- reduce wrinkling of the skin
- Peptide bioavailability enhancer
- Acidity Buffer
- Added to the formulation to buffer the acidity of the stomach; sparing the active peptide ingredients from degradation by the proteolytic enzyme, pepsinogen
- An acidic stomach is required to convert pepsin to pepsinogen, by buffering the pH we can lower the amount of active pepsinogen.
“I love this product. I haven’t had an upset belly in weeks. Most of my pain is also gone which i wasn’t expecting. So so good!”
I was skeptical of this product because I’d tried heaps of different gut supplements before that didn’t work, but after using GI Repair for only 3 days I noticed a hufe difference in my reflux and bloating! the issue is completely fixed now! thank you guys!
Great product. Highly recommend. Quick turnaround time on orders.
"I used to get a lot of pain and discomfort after certain foods, but I can even enjoy dairy now!!!"
"Wheat, dairy and a many other foods no longer effect me! this is awesome because they used to cause me so much pain and bloating, and now, nothing!! Soo happy!"
"This product has completely changed my digestion, I literally never get bloated or sluggish anymore. And surprisingly the asthma I’ve had since 6yrs old has disappeared. Nothing else I’ve tried has been so anti-inflammatory and healing. WOW!"
"Have actually been using BPC157 for a few years due to number of different injuries. Its so great to finally find a reputable company . Keep up the good work guys."
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026.
Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. BiochemPharmacol. 2001;61(5):613-21.
Haddad JJ, Lauterbach R, Saadé NE, Safieh-garabedian B, Land SC. Alpha-melanocyte-related tripeptide, Lys-d-Pro-Val, ameliorates endotoxin-induced nuclear factor kappaB translocation and activation: evidence for involvement of an interleukin-1beta193-195 receptor antagonism in the alveolar epithelium. Biochem J. 2001;355(Pt 1):29-38.
Rajora N, Boccoli G, Catania A, et al. α-MSH modulates experimental inflammatory bowel disease. Peptides. 1997;18:381–385.
Oktar BK, Ercan F, Ye en BC, et al. The effect of α-melanocyte stimulating hormone on colonic inflammation in the rat. Peptides. 2000;21:1271–1277.
Kelly JM, Moir AJ, Carlson K, et al. Immobilized α-melanocyte stimulating hormone 10–13 (GKPV) inhibits tumor necrosis factor-α stimulated NF-κB activity. Peptide. 2006;27:431–437.
Cooper A, Robinson SJ, Pickard C, et al. α-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol. 2005;175:4806–4813.
Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-4.
Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J PharmacolExpTher. 2003;306(2):631-7.
Schiöth HB, Muceniece R, Mutule I, Wikberg JE. New melanocortin 1 receptor binding motif based on the C-terminal sequence of alpha-melanocyte-stimulating hormone. Basic ClinPharmacolToxicol. 2006;99(4):287-93.
Kelly JM, Moir AJ, Carlson K, Yang Y, Macneil S, Haycock JW. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. 2006;27(2):431-7.
Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. AdvExp Med Biol. 2010;681:107-16.
Luger T A, Scholzen T, Grabbe S. The role of α‐melanocyte stimulating hormone in cutaneous biology. J Invest DermatolSympProc 1997287–93.
Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.
Grabbe S, Bhardwaj R S, Steinert M, Mahnke K, Simon M M, Schwarz T. et al Alpha‐melanocyte stimulating hormone induces hapten‐specific tolerance in mice. J Immunol 1996156473–478.
Bohm M, Eickelmann M, Li Z, Schneider S W, Oji V, Diederichs S. et al Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha‐melanocyte‐stimulating hormone in human dermal papilla cells. Endocrinology 20051464635–4646.
Scholzen T E, Sunderkotter C, Kalden D H, Brzoska T, Fastrich M, Fisbeck T. et al Alpha‐melanocyte stimulating hormone prevents lipopolysaccharide‐induced vasculitis by down‐regulating endothelial cell adhesion molecule expression. Endocrinology 2003144360–370.
Klaus Kannengiesser, MD, Christian Maaser, MD, Jan Heidemann, MD, Andreas Luegering, MD, Matthias Ross, MD, Thomas Brzoska, PhD, Markus Bohm, MD, Thomas A. Luger, MD, Wolfram Domschke, MD, Torsten Kucharzik, MD, Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, Inflammatory Bowel Diseases, Volume 14, Issue 3, 1 March 2008, Pages 324–331, https://doi.org/10.1002/ibd.20334.
Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017 Jul 5;25(7):1628-1640. doi: 10.1016/j.ymthe.2016.11.020. Epub 2017 Jan 28. PMID: 28143741; PMCID: PMC5498804.Available athttps://pubs.rsc.org/en/content/articlehtml/2022/bm/d1bm01466h.
Rheins L A, Cotleur A L, Kleier R S, Hoppenjans W B, Sauder D N, Nordlund J J. Alpha‐melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J Invest Dermatol 198993511–517.
Elliott R J, Szabo M, Wagner M J, Kemp E H, MacNeil S, Haycock J W. alpha‐Melanocyte‐stimulating hormone, MSH 11‐13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 20041221010–1019.Getting S J, Schioth H B, Perretti M. Dissection of the anti‐inflammatory effect of the core and C‐terminal (KPV) alpha‐melanocyte‐stimulating hormone peptides. J PharmacolExpTher 2003306631–637.
Luger T A, Scholzen T E, Brzoska T, Bohm M. New insights into the functions of alpha‐MSH and related peptides in the immune system. Ann N Y AcadSci 2003994133–140.
Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 200080979–1020.
Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol. 2005;175(7):4806-13.
Bohm M, Apel M, Sugawara K, et al. Modulation of basophil activity: a novel function of the neuropeptide α-melanocyte-stimulating hormone. J Allergy ClinImmunol. 2012;129(4):1085-93.
Redondo P, García-foncillas J, Okroujnov I, Bandrés E. Alpha-MSH regulates interleukin-10 expression by human keratinocytes. Arch Dermatol Res. 1998;290(8):425-8.
Rheins LA, Cotleur AL, Kleier RS, Hoppenjans WB, Saunder DN, Nordlund JJ. Alpha-melanocyte stimulating hormone modulates contact hypersensitivity responsiveness in C57/BL6 mice. J Invest Dermatol. 1989;93(4):511-7.
Morandini R, Boeynaems JM, Hedley SJ, MacNeil S , Ghanem G 1998 Modulation of ICAM-1 expression by α-MSH in human melanoma cells and melanocytes. J Cell Physiol175:276–282.
Kalden DH, Scholzen T, Brzoska T, Luger TA 1999 Mechanisms of the antiinflammatory effects of α-MSH. Role of transcription factor NF-κB and adhesion molecule expression. Ann NY AcadSci 885:254–261.
Scholzen TE, Sunderkötter C, Kalden DH, Brzoska T, Fastrich M, Fisbeck T, Armstrong CA, Ansel JC, Luger TA 2003 α-Melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 144:360–370.
Bohm M, Eickelmann M, Li Z, Schneider SW, Oji V, Diederichs S, Barsh GS, Vogt A, Stieler K, Blume-Peytavi U, Luger TA 2005 Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of α-melanocyte-stimulating hormone in human dermal papilla cells. Endocrinology 146:4635–4646.
Hill RP, MacNeil S, Haycock JW 2006 Melanocyte stimulating hormone peptides inhibit TNF-α signaling in human dermal fibroblast cells. Peptides 27:421–430.
Sarkar A, Sreenivasan Y, Manna SK 2003 α-Melanocyte-stimulating hormone induces cell death in mast cells: involvement of NF-κB. FEBS Lett 549:87–93.
Glyn JR, Lipton JM. Hypothermic and antipyretic effects of centrally administered ACTH (1–24) and alpha-melanotropin. Peptides. 1981;2(2):177-87.
Glyn-ballinger JR, Bernardini GL, Lipton JM. alpha-MSH injected into the septal region reduces fever in rabbits. Peptides. 1983;4(2):199-203.
Murphy MT, Lipton JM. Peripheral administration of alpha-MSH reduces fever in older and younger rabbits. Peptides. 1982;3(5):775-9.
Murphy MT, Richards DB, Lipton JM. Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. Science. 1983;221(4606):192-3.
Kandasamy SB, Williams BA. Hypothermic and antipyretic effects of ACTH (1-24) and alpha-melanotropin in guinea-pigs. Neuropharmacology. 1984;23(1):49-53.
Shih ST, Lipton JM. Intravenous alpha-MSH reduces fever in the squirrel monkey. Peptides. 1985;6(4):685-7.
Daynes RA, Robertson BA, Cho BH, Burnham DK, Newton R. Alpha-melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responses in vivo and in vitro. J Immunol. 1987;139(1):103-9.
Deeter LB, Martin LW, Lipton JM. Antipyretic effect of central alpha-MSH summates with that of acetaminophen or ibuprofen. Brain Res Bull. 1989;23(6):573-5.
Martin LW, Lipton JM. Acute phase response to endotoxin: rise in plasma alpha-MSH and effects of alpha-MSH injection. Am J Physiol. 1990;259(4 Pt 2):R768-72.
Feng JD, Dao T, Lipton JM. Effects of preoptic microinjections of alpha-MSH on fever and normal temperature control in rabbits. Brain Res Bull. 1987;18(4):473-7.Tatro JB 2000 Melanocortin receptor expression and function in the nervous system. In: Cone RD , ed. The melanocortin receptors. Totowa, NJ: Humana Press; 173–207.Tatro JB 2000 Endogenous antipyretics. Clin Infect Dis 21:S190–S201.
Rezvani AH, Denbow DM, Myers RD. alpha-Melanocyte-stimulating hormone infused ICV fails to affect body temperature or endotoxin fever in the cat. Brain Res Bull. 1986;16(1):99-105.
Greenberg R, Whalley CE, Jourdikian F, Mendelson IS, Walter R, Nikolics K, Coy DH, Schally AV, Kastin AJ 1976 Peptides readily penetrate the blood-brain barrier: uptake of peptides by synaptosomes is passive. PharmacolBiochemBehav 5(Suppl 1):151–158.Tatro JB, Sinha PS. The central melanocortin system and fever. Ann N Y Acad Sci. 2003;994:246-57.
Sinha PS, Schiöth HB, Tatro JB. Roles of the melanocortin-4 receptor in antipyretic and hyperthermic actions of centrally administered alpha-MSH. Brain Res. 2004;1001(1-2):150-8.
Huang QH, Entwistle ML, Alvaro JD, Duman RS, Hruby VJ, Tatro JB. Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin-induced fever. J Neurosci. 1997;17(9):3343-51.
Han D, Tian Y, Zhang M, Zhou Z, Lu J. Prevention and treatment of experimental autoimmune encephalomyelitis with recombinant adeno-associated virus-mediated alpha-melanocyte-stimulating hormone-transduced PLP139-151-specific T cells. Gene Ther. 2007;14(5):383-95.
Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation. 1994;1(1):28-32.
Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann N Y Acad Sci. 2000;917:239-47.
Nishida T, Miyata S, Itoh Y, et al. Anti-inflammatory effects of alpha-melanocyte-stimulating hormone against rat endotoxin-induced uveitis and the time course of inflammatory agents in aqueous humor. IntImmunopharmacol. 2004;4(8):1059-66.
Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol. 2002;72(5):946-52.
Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11(12):1199-206.
Naveh N, Marshall J. Melanocortins are comparable to corticosteroids as inhibitors of traumatic ocular inflammation in rabbits. Graefes Arch ClinExpOphthalmol. 2001;239(11):840-4.
Jahovic N, Arbak S, Tekeli O, Alican I. Alpha-melanocyte stimulating hormone has beneficial effects on cerulein-induced acute pancreatitis. Peptides. 2004;25(1):129-32.
Al-majed HT, Jones PM, Persaud SJ, et al. ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. J Endocrinol. 2004;180(1):155-66.
Jung EJ, Han DJ, Chang SH, et al. Protective effect of alpha-melanocyte-stimulating hormone on pancreas islet cell against peripheral blood mononuclear cell-mediated cytotoxicity in vitro. Transplant Proc. 2007;39(5):1604-6.
Strand FL, Zuccarelli LA, Williams KA, et al. Melanotropins as growth factors. Ann N Y Acad Sci. 1993;680:29-50.Gispen WH. The potential of melanotropins in the treatment of nervous system diseases. Ann N Y Acad Sci. 1993;680:401-11.
Gispen WH, Adan RA. Melanocortins and the treatment of nervous system disease. Potential relevance to the skin?. Ann N Y Acad Sci. 1999;885:342-9.
Sharma HS. Neuroprotective effects of neurotrophins and melanocortins in spinal cord injury: an experimental study in the rat using pharmacological and morphological approaches. Ann N Y Acad Sci. 2005;1053:407-21.
Bar PR, Mandys V, Turecek R, Gispen WH. Alpha-melanocyte-stimulating hormone has protective properties against the toxic effect of cisplatin on cultured dorsal root ganglia. Ann N Y Acad Sci. 1993;680:649-51.
Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliaryneurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology. 1994;44(3 Pt 1):488-94.
Chai B, Li JY, Zhang W, Newman E, Ammori J, Mulholland MW. Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase. Peptides. 2006;27(11):2846-57.
Caruso C, Durand D, Schiöth HB, Rey R, Seilicovich A, Lasaga M. Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon-gamma in astrocytes. Endocrinology. 2007;148(10):4918-26.
Bohm M, Wolff I, Scholzen TE, et al. alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2005;280(7):5795-802.
Kadekaro AL, Kavanagh R, Kanto H, et al. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res. 2005;65(10):4292-9.
Abdel-malek ZA, Kadekaro AL, Kavanagh RJ, et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J. 2006;20(9):1561-3.
Hill RP, Wheeler P, Macneil S, Haycock JW. Alpha-melanocyte stimulating hormone cytoprotective biology in human dermal fibroblast cells. Peptides. 2005;26(7):1150-8.
Kokot A , Sindrilaru A , Schiller S , Sunderkötter C , Kerkhoff C , Scharffetter-Kochanek K , Luger TA , Böhm M 2008 α-Melanocyte-stimulating hormone is a powerful agent in the bleomycin model of collagen synthesis and fibrosis. ExpDermatol 17:286.
Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. ExpDermatol. 2005;14(2):81-95.
Bohm M, Raghunath M, Sunderkötter C, et al. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem. 2004;279(8):6959-66.
Lee TH, Jawan B, Chou WY, et al. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med. 2006;8(6):764-72.
Edwards PM, Van der zee CE, Verhaagen J, Schotman P, Jennekens FG, Gispen WH. Evidence that the neurotrophic actions of alpha-MSH may derive from its ability to mimick the actions of a peptide formed in degenerating nerve stumps. J Neurol Sci. 1984;64(3):333-40.
Vadoudseyedi J, Liénard D, Lespagnard L, Ghanem G, Van wijck R, Lejeune F. Local administration of alpha-MSH exerts a trophic effect on the 200-kDa neurofilament in sciatic rat nerve. Ann N Y Acad Sci. 1993;680:655-9.
Van de meent H, Hamers FP, Lankhorst AJ, Joosten EA, Gispen WH. Beneficial effects of the melanocortin alpha-melanocyte-stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury. Neurosurgery. 1997;40(1):122-30.
Lankhorst AJ, Duis SE, Terlaak MP, Joosten EA, Hamers FP, Gispen WH. Functional recovery after central infusion of alpha-melanocyte-stimulating hormone in rats with spinal cord contusion injury. J Neurotrauma. 1999;16(4):323-31.
Joosten EA, Majewska B, Houweling DA, Bär PR, Gispen WH. Alpha-melanocyte stimulating hormone promotes regrowth of injured axons in the adult rat spinal cord. J Neurotrauma. 1999;16(6):543-53.
Sharma HS, Skottner A, Lundstedt T, Flärdh M, Wiklund L. Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors. J Neural Transm (Vienna). 2006;113(4):463-76.
Huh SK, Lipton JM, Batjer HH. The protective effects of alpha-melanocyte stimulating hormone on canine brain stem ischemia. Neurosurgery. 1997;40(1):132-9.
Huang Q, Tatro JB. Alpha-melanocyte stimulating hormone suppresses intracerebral tumor necrosis factor-alpha and interleukin-1beta gene expression following transient cerebral ischemia in mice. NeurosciLett. 2002;334(3):186-90.
Spulber S, Moldovan M, Oprica M, et al. Alpha-MSH decreases core and brain temperature during global cerebral ischemia in rats. Neuroreport. 2005;16(1):69-72.
Forslinaronsson S, Spulber S, Popescu LM, et al. alpha-Melanocyte-stimulating hormone is neuroprotective in rat global cerebral ischemia. Neuropeptides. 2006;40(1):65-75.
Giuliani D, Leone S, Mioni C, et al. Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. Eur J Pharmacol. 2006;538(1-3):48-56.
Giuliani D, Ottani A, Mioni C, et al. Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. Eur J Pharmacol. 2007;570(1-3):57-65.
Giuliani D, Mioni C, Altavilla D, et al. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology. 2006;147(3):1126-35.
Vecsernyes M, Juhasz B, Der P, et al. The administration of alpha-melanocyte-stimulating hormone protects the ischemic/reperfused myocardium. Eur J Pharmacol. 2003;470(3):177-83.
Mioni C, Giuliani D , Cainazzo MM, Leone S, Bazzani C, Grieco P, Novellino E, Tomasi A, Bertolini A, Guarini S 2004 Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors. Eur J Pharmacol 477:227–234.
Bertolini A, Guarini S, Rompianesi E, Ferrari W. Alpha-MSH and other ACTH fragments improve cardiovascular function and survival in experimental hemorrhagic shock. Eur J Pharmacol. 1986;130(1-2):19-26.
Guarini S, Schiöth HB, Mioni C, et al. MC(3) receptors are involved in the protective effect of melanocortins in myocardial ischemia/reperfusion-induced arrhythmias. NaunynSchmiedebergs Arch Pharmacol. 2002;366(2):177-82.
Yamaoka-tojo M, Tojo T, Shioi T, Masuda T, Inomata T, Izumi T. Central neurotranspeptide, alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure. Intern Med. 2006;45(7):429-34.
Chiao H, Kohda Y, Mcleroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest. 1997;99(6):1165-72.
Jo SK, Yun SY, Chang KH, et al. alpha-MSH decreases apoptosis in ischaemic acute renal failure in rats: possible mechanism of this beneficial effect. Nephrol Dial Transplant. 2001;16(8):1583-91.
Kwon TH, Frøkiaer J, Fernández-llama P, Knepper MA, Nielsen S. Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: prevention by alpha-MSH. Am J Physiol. 1999;277(3):F413-27.
Gong H, Wang W, Kwon TH, et al. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004;66(2):683-95.